Leadership
CUREVERSE was founded by experts in small molecule drug discovery, brain disease therapeutics, and medicinal chemistry, who united with the shared goal of developing novel treatments for intractable brain disorders.
CNS Drug Development Professional
Ki Duk Park
PhD/ Co-Founder
- CNS Drug Development Professional
- Head of KIST Brain Science Institute
- Lead Pipeline Technology Inventor
- Ph.D., M.S., and B.S. in Biotechnology, Yonsei University
- Postdoctoral Researcher, Korea Research Institute of Bioscience and Biotechnology (KRIBB)
- Postdoctoral Researcher, UNC Eshelman School of Pharmacy (University of North Carolina)Research in Epilepsy Treatment Technology
- Head, KIST Brain Science Institute
- Associate/Full Professor, UST KIST School
- Specialized Researcher in Brain Disease Treatment Technology Development
- Key Publications
Over 90 SCI-indexed papers
- Journal of Medicinal Chemistry (JMC): Papers published in 2019, 2021 and 2022
- European Journal of Medicinal Chemistry (EJMC): Papers published in 2019, 2020 and 2021
- Science Advances: Papers published in 2019
- License Out Deal
- 2020: Spinal Cord Injury & Stroke Treatment
- 2019: Antifungal Treatment (Global Phase 1 Clinical Trial)
- 2017: Antifungal Treatment
- 2017: Dementia Treatment (Phase 1 Clinical Trial)
- Awards & Honors
- 2020, 2017: KISTian of the Month Award (or KIST Person of the Month Award)
- 2018: Selected as one of the Top 100 National R&D Achievements
- 2017: Minister’s Award from the Ministry of Science and ICT (Distinguished Service in Biotechnology)
